ITGR · Integer Holdings Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Leverage ratio non-GAAP | 3.2 | July 3, 2026 | — |
| Organic sales change non-GAAP | -1.5% | Three Months Ended July 3, 2026 | — |
| Non-GAAP net total debt non-GAAP | $1.26B | as of April 3, 2026 | — |
| Adjusted EPS non-GAAP | $1.76 | Three Months Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ITGR
this stock
Integer Holdings Corp
|
$4.25B | +59.4% | +16.9% | 34.0 | 12.8% |
|
ABT
Abbott Laboratories
|
$184.13B | -14.1% | +5.7% | 29.6 | 1.4% |
|
SYK
Stryker Corp
|
$129.28B | -3.6% | +11.2% | 34.9 | 1.8% |
|
MDT
Medtronic plc
|
$110.07B | -8.9% | +8.4% | 23.1 | 1.5% |
|
BSX
Boston Scientific Corp
|
$69.19B | -49.9% | +5.5% | 19.3 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ITGR | +25.2% | +37.1% | +43.4% | +3.1% | +59.4% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | +19.7% | +33.9% | +32.1% | +0.1% | +46.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.